Logo image of EVFM

EVOFEM BIOSCIENCES INC (EVFM) Stock Fundamental Analysis

NASDAQ:EVFM - Nasdaq - US30048L2034 - Common Stock - Currency: USD

0.4782  -0.15 (-23.37%)

After market: 0.4405 -0.04 (-7.88%)

Fundamental Rating

2

Taking everything into account, EVFM scores 2 out of 10 in our fundamental rating. EVFM was compared to 198 industry peers in the Pharmaceuticals industry. EVFM scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. EVFM is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year EVFM has reported negative net income.
EVFM Yearly Net Income VS EBIT VS OCF VS FCFEVFM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 -50M -100M -150M -200M

1.2 Ratios

Industry RankSector Rank
ROA -552.28%
ROE N/A
ROIC 99.62%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
EVFM Yearly ROA, ROE, ROICEVFM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 0 -2K -4K -6K -8K -10K

1.3 Margins

Industry RankSector Rank
OM -1324.48%
PM (TTM) -1676.29%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
EVFM Yearly Profit, Operating, Gross MarginsEVFM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 0 -10K -20K -30K

More info and screens

4

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), EVFM is creating value.
Compared to 1 year ago, EVFM has less shares outstanding
The debt/assets ratio for EVFM is higher compared to a year ago.
EVFM Yearly Shares OutstandingEVFM Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M
EVFM Yearly Total Debt VS Total AssetsEVFM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M 100M

2.2 Solvency

EVFM has an Altman-Z score of -55.10. This is a bad value and indicates that EVFM is not financially healthy and even has some risk of bankruptcy.
EVFM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -55.1
ROIC/WACC11.33
WACC8.79%
EVFM Yearly LT Debt VS Equity VS FCFEVFM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 0 -50M -100M

2.3 Liquidity

EVFM has a Current Ratio of 0.14. This is a bad value and indicates that EVFM is not financially healthy enough and could expect problems in meeting its short term obligations.
EVFM has a Quick Ratio of 0.14. This is a bad value and indicates that EVFM is not financially healthy enough and could expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 0.14
Quick Ratio 0.1
EVFM Yearly Current Assets VS Current LiabilitesEVFM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M 100M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for EVFM have decreased strongly by -553.85% in the last year.
EVFM shows a strong growth in Revenue. In the last year, the Revenue has grown by 630.13%.
EPS 1Y (TTM)-553.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-414.29%
Revenue 1Y (TTM)630.13%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%282.97%

3.2 Future

The Earnings Per Share is expected to grow by 13.45% on average over the next years. This is quite good.
Based on estimates for the next years, EVFM will show a very strong growth in Revenue. The Revenue will grow by 106.58% on average per year.
EPS Next Y57.85%
EPS Next 2Y38.15%
EPS Next 3Y25.03%
EPS Next 5Y13.45%
Revenue Next Year295.01%
Revenue Next 2Y172.93%
Revenue Next 3Y130.74%
Revenue Next 5Y106.58%

3.3 Evolution

EVFM Yearly Revenue VS EstimatesEVFM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 100M 200M 300M
EVFM Yearly EPS VS EstimatesEVFM Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2018 2019 2020 2021 2022 2023 2024 2025 2026 -20 -40 -60 -80

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for EVFM. In the last year negative earnings were reported.
Also next year EVFM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EVFM Price Earnings VS Forward Price EarningsEVFM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -0.88
EVFM Per share dataEVFM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15

4.3 Compensation for Growth

EVFM's earnings are expected to grow with 25.03% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.15%
EPS Next 3Y25.03%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for EVFM!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EVOFEM BIOSCIENCES INC

NASDAQ:EVFM (8/10/2022, 8:00:02 PM)

After market: 0.4405 -0.04 (-7.88%)

0.4782

-0.15 (-23.37%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-04 2022-08-04/amc
Earnings (Next)11-14 2022-11-14
Inst Owners0%
Inst Owner Change-99.93%
Ins Owners25.96%
Ins Owner Change0%
Market Cap20.18M
Analysts80
Price Target11.27 (2256.75%)
Short Float %0.06%
Short Ratio0
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.77
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA -0.88
EPS(TTM)-15.3
EYN/A
EPS(NY)-1.19
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.27
BVpS-2.94
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -552.28%
ROE N/A
ROCE N/A
ROIC 99.62%
ROICexc N/A
ROICexgc 99.62%
OM -1324.48%
PM (TTM) -1676.29%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.33
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.14
Quick Ratio 0.1
Altman-Z -55.1
F-Score4
WACC8.79%
ROIC/WACC11.33
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-553.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-414.29%
EPS Next Y57.85%
EPS Next 2Y38.15%
EPS Next 3Y25.03%
EPS Next 5Y13.45%
Revenue 1Y (TTM)630.13%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%282.97%
Revenue Next Year295.01%
Revenue Next 2Y172.93%
Revenue Next 3Y130.74%
Revenue Next 5Y106.58%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A